uric acid and act-132577

uric acid has been researched along with act-132577 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Bellet, M; Danaietash, P; Flamion, B; Ménard, J; Verweij, P	1
Burnier, M; Dingemanse, J; Flamion, B; Gueneau de Mussy, P; Guérard, N; Iglarz, M; Maillard, MP; Sidharta, PN; Wuerzner, G	1

Trials

2 trial(s) available for uric acid and act-132577

Article	Year
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. Hypertension (Dallas, Tex. : 1979), 2020, Volume: 75, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Hematocrit; Humans; Hypertension; Male; Middle Aged; Pyrimidines; Serum Albumin; Sulfonamides; Treatment Outcome; Uric Acid	2020
Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:3 Topics: Administration, Oral; Adult; Aldosterone; Body Water; Cross-Over Studies; Double-Blind Method; Endothelin Receptor Antagonists; Glycopeptides; Healthy Volunteers; Homeostasis; Humans; Male; Middle Aged; Natriuresis; Pyrimidines; Sodium, Dietary; Sulfonamides; Switzerland; Uric Acid; Water-Electrolyte Balance; Weight Gain; Young Adult	2021

Article

Year

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.

Hypertension (Dallas, Tex. : 1979), 2020, Volume: 75, Issue:4

Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Hematocrit; Humans; Hypertension; Male; Middle Aged; Pyrimidines; Serum Albumin; Sulfonamides; Treatment Outcome; Uric Acid

2020

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.

Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:3

Topics: Administration, Oral; Adult; Aldosterone; Body Water; Cross-Over Studies; Double-Blind Method; Endothelin Receptor Antagonists; Glycopeptides; Healthy Volunteers; Homeostasis; Humans; Male; Middle Aged; Natriuresis; Pyrimidines; Sodium, Dietary; Sulfonamides; Switzerland; Uric Acid; Water-Electrolyte Balance; Weight Gain; Young Adult

2021